Kornimate/medical-research-clean huggingface dataset:
teen chat: improving physician communication with adolescents about healthy weight

Conditions: Communication; Obesity; Nutrition; Physical Activity; Sleep

Summary: the purpose of this study is to teach primary care physicians effective ways to counsel overweight and obese adolescent patients to attain a healthy weight. fifty physicians and up to 660 adolescent patients from duke university health system (duhs) primary care clinics will take part in this study. patients will be identified by research study staff and asked if they would be willing to have their clinic visit audio recorded for research purposes. there are three phases of data collection. first, baseline encounters (n=200, 4 per physician) are audio recorded. then, half of the physicians will be randomized to receive a tailored web-based intervention containing information about evidence-based techniques to help adolescents attain a healthy weight. a new set of 200 encounters (4 per physician) will be audio recorded. then, all physicians will receive a summary report that outlines the adolescent's high risk behaviors that contribute to weight (sweetened beverages, fast food, breakfast, physical activity, screen time, and sleep) and a new set of 200 encounters will be audio recorded. data will be collected by trained data technicians, in-person and over the phone. data is collected on laptop computers and then downloaded into password protected electronic files on a secure network server. all participants (adolescent patients and physicians) will be assigned a code number that is the sole identifier on all study data forms. prior to and after coding, digital files will be stored in password protected directories to which only the data technicians and project manager have access. the web-based intervention will be password protected.


Eligibility criteria:
inclusion criteria for mds: * specialty is family practice or pediatrics * located in participating clinic * not planning to leave clinic in the next two years inclusion criteria for teen patients: * english-speaking * bmi z-score \>85th percentile * age 12-18 * not pregnant * have parental consent to participate if over 18 * have visit at least 7 days in the future * have access to a telephone exclusion criteria for teen patients: * bmi z-score \<85th percentile * not english speaking * pregnant * \<12 or older than 18 * incompetent for interview * seen primarily by non-physician provider
physiologic cardiac pacing to prevent left ventricular dysfunction post tavi

Conditions: Atrioventricular Block, Second and Third Degree

Summary: the study aims to compare permanent conduction system pacing (csp) with the standard therapy - right ventricular pacing (rvp) or biventricular pacing (bvp) - in preventing the development and progression of symptomatic chronic heart failure (chf) and improving survival in patients after transcatheter aortic valve implantation (tavi).

a multicenter randomized controlled head-to-head trial was planned to compare the effects of permanent pacemaker implantation (ppmi) using csp (study intervention) with currently standard therapy - rvp or bvp (control group). the study population will consist of patients hospitalized after tavi complicated with high-degree persistent atrioventricular (av) block or newly developed complex av or intraventricular conduction disturbances, qualified for ppmi within 30 days after surgery, following the 2021 european society of cardiology (esc) guidelines on cardiac pacing and cardiac resynchronization therapy.

Eligibility criteria:
inclusion criteria: 1. transcatheter aortic valve implantation (tavi) in up to 30 days before qualification to pacemaker implantation 2. fulfilled criteria for permanent pacemaker implantation according do 2021 esc guidelines 3. written informed consent 4. age of at least 18 years exclusion criteria: 1. permanent pacemaker implantation before tavi procedure 2. the occurrence of conduction disturbances more than 30 days after tavi procedure 3. no written informed consent 4. inability to obtain informed consent from participant 5. predicted inability to obtain cooperation from patient during observation period

Keywords: pacemaker transcatheter aortic valve replacement conduction system pacing (csp) atrioventricular block congestive heart failure bradycardia
music therapy for women, delivered via cesarean section

Conditions: Cesarean Section; Postpartum Period

Summary: musical therapy is a type of therapy which is performed under a regular method by adjusting the physiological and psychological effects of musical tones and melodies in accordance with various situations. therefore, the study was carried out as a randomized controlled trial in order to evaluate the effect of music therapy on the level of pain and anxiety in the postpartum period in women who delivered via cesarean section.

objectives: the study was carried out in order to determine the effect of music therapy on the level of postpartum pain and anxiety in women who delivered via cesarean section. design, setting and subjects: the randomized controlled trial was conducted on 126 women who delivered via cesarean section in a tertiary hospital. the subjects were allocated to three groups (n=42 each) interventions: in the experimental group 1 (once a day) and group 2 (twice a day) were made to listen to music for 30 minutes for two consecutive days. the control group routine care of 30 min a day in bed rest. the personal information form, visual analog scale, state-trait anxiety inventory were administered to participants. in the analysis of the data, one-way anova, paired t-test, kruskal wallis-h and wilcoxon tests were used. main outcome measures: state anxiety level and pain level.

Eligibility criteria:
inclusion criteria: * being at the age of 18 and above, * being healthy, * having given a live birth, * having no hearing impairment, * complication not having developed either in the mother or the baby exclusion criteria: * being at the age of 17 and below, * being unhealthy, * having given a stillbirth, * having hearing impairment, * complication having developed either in the mother or the baby

Keywords: cesarean section music therapy anxiety pain
evaluation of mechanical stapler for aortic anastomoses

Conditions: Aortic Aneurysm, Abdominal; Leriche Syndrome

Summary: demonstrate the safety and performance of the aortic stapler when used to attach a synthetic graft to an aorta in aaa and leriche syndrome patients


Eligibility criteria:
inclusion criteria: * patient age is between 21 to 85 years old. * patient is diagnosed with abdominal aortic aneurysm (aaa) or -aorto-iliac/femoral occlusive arterial disease (leriche' syndrome) by ct-angio examination and/or angiography examination in patients with leriche' syndrome. * patient with an aneurysm at the neck of the proximal or distal site that is between 5 to 10 mm and with a diameter of 16-22 mm. * patient is scheduled for aaa repair exclusion criteria: * pregnant women * active malignancy * ruptured aneurysm * thoraco-aaa * patient with at least one of the following unstable risk factors: * renal disease (cr \>2) * ischemic heart disease (unstable angina) * obstructive pulmonary disease (contraindicated for open aortic surgery by respiratory function exam) * severe chf (ef \< 25%) * patient with known allergy to metals or to the contrast media * participation in current or recent (within 60 days prior to surgery) clinical trial
sub-threshold pacing to prevent pacemaker-induced ventricular tachycardia

Conditions: Ventricular Tachyarrhythmias; ICD Shock Therapy; ICD Shock Burden

Summary: implantable cardioverter defibrillators (icd) may have the capacity to provoke or worsen ventricular tachyarrhythmias (vt). it has been reported that icd shocks by itself can increase mortality. this study aimed to determine the role of back-up pacing-induced vt (pit) to the overall icd shock burden by avoiding pause-related ventricular back-up pacing by programming the pacing output to a sub-threshold level for ineffective pacing.


Eligibility criteria:
inclusion criteria: * age \> 18 years * implanted icd * occurrence of pacemaker-induced vt exclusion criteria: * documentation of pause-related syncope * av block * sick-sinus syndrome * younger than 18 years

Keywords: icd ventricular tachyarrhythmia shock sub-threshold pacing
acute treatment and long-term assessment of adult infectious meningitis

Conditions: Viral Meningitis; Bacterial Meningitis; Fungal Meningitis; Meningitis

Summary: prospective, multicenter, observational clinical registry of adult patients with acute infectious meningitis across approximately 30 public and private hospitals in brazil. the study will include adults, 18 years old and older, with suspected acute infectious meningitis. data will be collected during hospitalization and post-discharge to evaluate clinical management, treatment and short and long-term outcomes. the study aims to generate real-world evidence on current practices and outcomes to support improvements in national care protocols.

this is a middle-income real-world prospective clinical registry study. clinical and laboratory data will be collected during hospitalization and follow-up visits after discharge. data collection will include empirical antibiotic therapy timing and type, time from hospital admission to antibiotic's first dose, corticosteroid therapy initiation, vaccination status per the brazilian national immunization program, neurological sequelae and access to specialized rehabilitation services post-discharge. primary outcomes will be all-cause mortality, length of hospital stay, rate of re- hospitalization and sensorineural hearing loss incidence. secondary outcomes will be etiology-specific mortality, functional outcomes (measured by modified rankin score and barthel index brazilian version), guideline-based therapies by etiology, neurological sequelae incidence stratified by etiology (e.g., motor deficits, cerebrovascular complications) , serious adverse events and access to rehabilitation. findings will be used to inform public health system and clinical care in brazil.

Eligibility criteria:
inclusion criteria: * fever (axillary temperature ≥37.8°c) followed by two or more of the following symptoms: severe headache, vomiting, altered consciousness (confusion, drowsiness, or irritability), photophobia (increased sensitivity to light), presence of seizures or * fever accompanied by at least one meningeal irritation sign, such as neck stiffness, kernig's sign, or brudzinski's sign or * sudden onset of fever and appearance of petechial skin rash or hemorrhagic suffusions exclusion criteria: - refusal to provide consent for study participation

Keywords: meningitis bacterial viral corticosteroids antibiotics fungal
decision aid to facilitate shared decision making during treatment in schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: we hypothesize that the use of a visual decision aid tool to educate patients regarding potential harm with respect to weight gain with olanzapine versus perphenazine can lead to better shared decision making by patients, increase rates of antipsychotic switches and promote weight loss in overweight patients with schizophrenia/schizoaffective disorder. our specific aims are the following: 1. to investigate the effects of a visual decision aid, versus care as usual, on patients' perceived difficulties in medical decision making regarding switching antipsychotics in overweight veterans with schizophrenia or schizoaffective disorder. 2. to investigate the effects of a visual decision aid and a shared decision making model on rate of medication switches (from olanzapine to perphenazine) in overweight veterans with schizophrenia or schizoaffective disorder. 3. to investigate the effects of a visual decision making aid and shared decision making model on bmi in overweight veterans who switch from olanzapine to perphenazine therapy.


Eligibility criteria:
inclusion criteria: * patients with diagnosis of schizophrenia or schizoaffective disorder as per by their medical record diagnosis. * patients currently on olanzapine therapy and bmi \>29.9. * patients treated with olanzapine for greater than or equal to 3 months prior to enrollment. * patient would be required to have either attempted dietary, lifestyles modifications and/or participated in weight loss programs. * patients with no history of psychiatric hospitalizations in past six months and judged by treating clinician to be suitable for antipsychotic medication switch. * patients with adequate decisional capacity to make a choice about participating in this research study. * patients, who are able to comprehend and satisfactorily comply with protocol requirements and have an ability to read and write english. * patients, who signed the written consent given prior to entering any study procedure. exclusion criteria: * patients with a history of treatment resistant schizophrenia or past trials with clozapine. * patients with a concurrent dsm-iv diagnosis of ptsd as per their medical record. * substance dependence or abuse (excluding nicotine) within one month prior to the screening visit. * patients with a history of non-response, intolerance or hypersensitivity ot perphenazine. * subjects with history of treatment of clozapine. * patients who based on history of mental status examination have a significant risk of committing suicide. * patients who are homicidal or violent and who are in the investigator's opinion in significant imminent risk of hurting others. * female patients who are pregnant, planning to become pregnant, or if of childbearing potential, not using an acceptable method of birth control. * patient currently receiving depot neuroleptics. * patients with visual impairments.

Keywords: schizophrenia schizoaffective disorder shared decision decision aid antipsychotic weight gain olanzapine lexapro perphenazine
evaluation of the effects of flat and modified inclined fixed anterior bite planes on mandibular position in growing females with skeletal class 2 malocclusion due to mandibular deficiency and deep bite

Conditions: Skeletal Class 2

Summary: this study will be conducted to see if unlocking mandible from deep bite in growing females by flat fixed anterior bite plane will change mandibular position in skeletal mandibular deficiency and if there is a difference in the change of mandibular position if we assisted the mandible by holding it in a more forward position by modified inclined fixed anterior bite plane .these results will be compared to normal mandibular growth from previous records of a matched control group in the discussion afterthat.

two groups of patients the first for flat fixed anterior bite plane, the second for modified inclined fixed anterior bite plane.full records are taken to patients. then bands selection for upper first molars,impressions for upper arch with bands fitted and impression to lower arch, fabrication of either flat/ modified inclined fixed anterior bite planes and cementation in patient's mouth,evaluation of results after 8 months.

Eligibility criteria:
inclusion criteria: * (1)growing females aged 10-13 (2)skeletal maturational stage: stages 3,4 of the cervical maturational index cvmi. (3) low-angle/moderate normal growth pattern (4) overjet of 4-7 mm as measured from labial surface of upper incisors to labial surface of lower incisors (5)skeletal class 2 due to mandibular deficiency 77 degrees \ 73 degrees (6) normal or slightly protruded maxillary base (7) all cases had dental deep bite; with the upper incisors covering more than 50% of the height of the lower incisors. (8)only deep bite cases that required extrusion of posterior teeth. exclusion criteria:1- no syndromic or medically compromised patients 2- no growth disorders 3- no use of other appliances before or during the period of functional treatment -
evaluation of safety and effects of slx-4090 after dosing for 14 days in subjects with high triglycerides

Conditions: Hypertriglyceridemia

Summary: the purpose is to investigate the effect of oral doses of slx-4090 over 14 days on subjects with high triglycerides.

1. serum triglycerides 2. serum lipids and lipoproteins 3. safety and tolerability

Eligibility criteria:
inclusion criteria: * male or female subjects with high triglyceride levels * male or female subjects between age 18 and 65 years, inclusive exclusion criteria: * history of drug abuse * any prescribed or over the counter medication taken within 2 weeks prior to administration of study drug or within 6 times the elimination half-life * blood donation of more than 500ml blood in the previous 3 months * any confirmed significant allergic reaction against any drug or multiple allergies
rtms and botulinum toxin in benign essential blepharospasm

Conditions: Benign Essential Blepharospasm

Summary: benign essential blepharospasm (beb) is a functionally disabling focal dystonia. botulinum neurotoxin (bont) therapy is suboptimal in many beb patients. repetitious transcranial magnetic stimulation (rtms) therapy is a promising noninvasive therapy and has shown positive benefits in beb. rtms therapy can be easily combined with bont injections to enhance the effects of bont in beb.

a two week course of rtms therapy to achieve sustained benefits will be employed. with standard bont treatment, the peak-dose benefits are seen at about 4-6 weeks after the administration of injections. rtms will be introduced during this peak-dose period (about 6 weeks after bont or t1).the effects of combined therapy at about 10 weeks after bont injections (t2) and at about 12 weeks after bont injections (t3) will be examined along with the physiological effects at these time points.

Eligibility criteria:
inclusion criteria: * subjects diagnosed with blepharospasm or cranio-cervical dystonia who receive bont therapy at the center for movement disorders will be approached. the investigators will enroll only those subjects who report experiencing positive benefits with bont but lasting about 10 weeks or less. exclusion criteria: * pregnancy * active seizure disorder * significant cognitive impairment * exposure to neuroleptics * presence of a metallic body such as pacemaker, implants, prosthesis, artificial limb or joint, shunt, metal rods and hearing aid.
single daily dose rifaximin for the treatment of travelers' diarrhea

Conditions: Travelers' Diarrhea

Summary: the study will compare durations of diarrhea among subjects who report to clinic for treatment and who receive either: 1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, or 2. a single 600 mg dose of rifaximin daily for 3 days.


Eligibility criteria:
inclusion criteria: * passage of 3 or more unformed stools in 24 hours plus an additional symptom of enteric disease such as abdominal cramps, nausea, vomiting, or fever; and investigator verification that an unformed stool has been submitted. * is \> 18 years of age * has diarrhea (at least three unformed stools in 24 hrs) plus at least one additional sign or symptom of enteric illness * has acute diarrhea less than 1 week's duration * willingness to provide a diarrhea stool sample * willingness to keep a daily diary for 5 days * signed informed consent exclusion criteria: * fever or bloody diarrhea * has taken predictably effective antibiotics in the past week (e.g. quinolones, tmp/smx, azalide or doxycycline) * is pregnant now, likely to become pregnant, or breast-feeding * has duration of diarrhea of greater than 1 weeks * is allergic to rifampin or rifaximin * has a history of significant underlying enteric, pulmonary, cardiac, renal disease, or any cns disorder * is more than moderately dehydrated

Keywords: diarrhea, travelers acute travelers' diarrhea
heart failure study to evaluate vital signs and overcome low use of guideline-directed therapy by remote monitoring

Conditions: Heart Failure

Summary: a study evaluating the impact of remotely collected data, measured using digital technologies, on the use of guideline-recommended heart failure therapy in adult participants with heart failure.


Eligibility criteria:
inclusion criteria: * history of chronic heart failure. * ejection fraction equal to or below 40%. * new york heart association (nyha) class ii to class iii. * enrollment during or within 30 days after a hospitalization, emergency department, or urgent, unscheduled clinic/office visit with primary diagnosis of heart failure. exclusion criteria: * has received a major organ transplant (e.g., lung, liver, heart, bone marrow, kidney). * currently in an investigational device or drug study. * unwilling or unable to wear a digital wrist watch device for measuring blood pressure and other parameters during waking hours.

Keywords: digital health remote monitoring wearable device
evaluation of the antimicrobial fiber reinforced composite resin space maintainer modified with silver nano particles

Conditions: Dental Caries in Children

Summary: fiber reinforced composite resin space maintainer

evaluation of the antimicrobial fiber reinforced composite resin space maintainer modified by silver nano particles.

Eligibility criteria:
inclusion criteria: * premature loss of primary molar. * presence of teeth on the mesial and distal sides of the extraction space. * normal primary molar relation. * no root resorption of abutment teeth. * presence of a succedaneous tooth bud. * absence of pathology on the eruption track of the succedaneous tooth. * the age will be ranged from 4 to 9 years. exclusion criteria: * carious buccal and lingual surface of abutment teeth. * absence of teeth on the mesial and distal sides of the extraction.
sodium nitrate to improve blood flow

Conditions: Becker Muscular Dystrophy

Summary: investigators recently showed that tadalafil restores functional sympatholysis in patients with becker muscular dystrophy (bmd). if tadalafil restores functional sympatholysis in bmd via the no-cyclic guanosine monophosphate pathway, then functional sympatholysis should also be restored by sodium nitrite- which is an indirect nitric oxide donor.


Eligibility criteria:
inclusion criteria: * becker muscular dystrophy * age 15-55 years of age * ambulatory exclusion criteria: * hypertension, diabetes, or heart failure by standard clinical criteria * elevated brain natriuretic peptide level (\>100 pg/ml) * left ventricular ejection fraction \< 50% * cardiac rhythm disorder, specifically: rhythm other than sinus, supraventricular tachycardia, atrial fibrillation, ventricular tachycardia, heart block * continuous ventilatory support * liver disease * renal impairment * history of asthma or bronchospasm * use of any medications other than common supplements * unable to perform handgrip exercise

Keywords: becker dystrophy sympatholysis
breast stereotactic radiotherapy to primary tumors in metastatic patients

Conditions: Stage IV Breast Cancer

Summary: this is a dose escalation study involving stage iv breast cancer patients not progressing after 6 months of first line systemic treatment. potential advantages of stereotactic body radiotherapy (sbrt) in treating breast primary tumor in metastatic breast cancer are: * radio-biological advantage of a short highly effective treatment schedule * possibility of preventing lesions to become symptomatic * possibility of continuing systemic treatment without interruption


Eligibility criteria:
inclusion criteria: * age: 18 years or older * histologically confirmed diagnosis of invasive breast carcinoma (biological immunohistochemical profile: luminal and/or human epidermal growth factor receptor 2 positive) * distant metastatic disease not progressing after 6 months of systemic therapy * zubrod performance status of 0-1 * unifocal tumour \< 5 cm tumor size * tumor ct or 18-labeled fluorodeoxyglucose positron emission tomography (5fdg-pet) detectable * no surgery being recommended at time of enrollment. exclusion criteria: * prior radiotherapy * active systemic lupus erythematosus, or any history of scleroderma, dermatomyositis with active rash * women who are pregnant or lactating. * psychiatric or addictive disorders that preclude obtaining informed consent or adherence to protocol